![The primary goal of the Paradigm Registry is to accelerate tumor profiling based on disease biology. [iStock/LilliDay]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/307-218x150.jpeg "AI Algorithm Could Reduce Breast Cancer Mammogram False Positive Rate")
Originally aired: January 31, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Multiplex immunofluorescence (mIF) assays offer the advantage of preserving the architectural features of the tumor microenvironment (TME) and revealing the spatial relationships between tumor cells and immune cells that are present. Using an Ultivue 8-plex mIF assay enabled the team to elucidate the T cell phenotypes spatially and quantitively in the context of Adaptimmune’s engineered SPEAR-T cell therapy infiltration within the TME. In this GEN and IPM Webinar, our distinguished presenters, Dr. Robyn Broad and Dr. Martin Isabelle, showed us examples of patient baseline and post-infusion biopsies for multiple indications to demonstrate how they uses these analyses to quantify cell densities of subsets of infiltrating immune cells and observe cellular spatial patterns within the tumors.
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.
Produced with support from:
Senior Scientist, Tumor Profiling, Translational Sciences
Adaptimmune
Group Leader, Tumor Profiling and Imaging, Translational Sciences
Adaptimmune